72 related articles for article (PubMed ID: 7831668)
1. On the immunogenicity of recombinant staphylokinase in patients and in animal models.
Vanderschueren SM; Stassen JM; Collen D
Thromb Haemost; 1994 Aug; 72(2):297-301. PubMed ID: 7831668
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and induction of circulating antibodies against recombinant staphylokinase.
Declerck PJ; Vanderschueren S; Billiet J; Moreau H; Collen D
Thromb Haemost; 1994 Jan; 71(1):129-33. PubMed ID: 8165631
[TBL] [Abstract][Full Text] [Related]
3. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.
Collen D; De Cock F; Stassen JM
Circulation; 1993 Mar; 87(3):996-1006. PubMed ID: 8443918
[TBL] [Abstract][Full Text] [Related]
4. Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction.
Collen D; Moreau H; Stockx L; Vanderschueren S
Circulation; 1996 Jul; 94(2):207-16. PubMed ID: 8674180
[TBL] [Abstract][Full Text] [Related]
5. [Staphylokinase for a better thrombolytic treatment of heart and platelet diseases].
Vanderschueren S
Verh K Acad Geneeskd Belg; 2000; 62(1):69-75. PubMed ID: 10769618
[TBL] [Abstract][Full Text] [Related]
6. A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis.
Vanderschueren S; Collen D; van de Werf F
Thromb Haemost; 1996 Oct; 76(4):541-4. PubMed ID: 8902993
[TBL] [Abstract][Full Text] [Related]
7. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.
Lijnen HR; Stassen JM; Vanlinthout I; Fukao H; Okada K; Matsuo O; Collen D
Thromb Haemost; 1991 Oct; 66(4):468-73. PubMed ID: 1796398
[TBL] [Abstract][Full Text] [Related]
8. Comparative antigenicity of recombinant wild-type staphylokinase (SakSTAR) and a selected mutant (SakSTAR.M38) in a baboon thrombolysis model.
Vanderschueren S; Stassen JM; Collen D
J Cardiovasc Pharmacol; 1996 Jun; 27(6):809-15. PubMed ID: 8761847
[TBL] [Abstract][Full Text] [Related]
9. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase.
Vanderschueren S; Stockx L; Wilms G; Lacroix H; Verhaeghe R; Vermylen J; Collen D
Circulation; 1995 Oct; 92(8):2050-7. PubMed ID: 7554181
[TBL] [Abstract][Full Text] [Related]
10. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction.
Collen D; Van de Werf F
Circulation; 1993 Jun; 87(6):1850-3. PubMed ID: 8504497
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action and thrombolytic potential of staphylokinase.
Lijnen HR
Verh K Acad Geneeskd Belg; 1995; 57(4):303-14. PubMed ID: 8571666
[TBL] [Abstract][Full Text] [Related]
12. Recombinant staphylokinase variants with altered immunoreactivity. IV: Identification of variants with reduced antibody induction but intact potency.
Collen D; Stockx L; Lacroix H; Suy R; Vanderschueren S
Circulation; 1997 Jan; 95(2):463-72. PubMed ID: 9008465
[TBL] [Abstract][Full Text] [Related]
13. Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis.
Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1995 May; 73(5):845-9. PubMed ID: 7482414
[TBL] [Abstract][Full Text] [Related]
14. Bio-immunoassay for staphylokinase in blood.
Lijnen HR; Beelen V; Declerck PJ; Collen D
Thromb Haemost; 1993 Sep; 70(3):491-4. PubMed ID: 8259555
[TBL] [Abstract][Full Text] [Related]
15. Humoral and cellular immune responses up to 7.5 years after administration of streptokinase for acute myocardial infarction.
Squire IB; Lawley W; Fletcher S; Holme E; Hillis WS; Hewitt C; Woods KL
Eur Heart J; 1999 Sep; 20(17):1245-52. PubMed ID: 10454976
[TBL] [Abstract][Full Text] [Related]
16. [Staphylokinase--a specific plasminogen activator].
Rozpończyk E; Szemraj J; Malinowski M; Rozpończyk J
Postepy Biochem; 2006; 52(1):80-6. PubMed ID: 16869305
[TBL] [Abstract][Full Text] [Related]
17. [Thrombolysis by staphylokinase in rabbits with experimental pulmonary embolus].
Liu X; Tang Z; Liang X; Ma X; Chen W
Yao Xue Xue Bao; 1998 Nov; 33(11):801-6. PubMed ID: 12016937
[TBL] [Abstract][Full Text] [Related]
18. Functional properties of p-anisoylated plasmin-staphylokinase complex.
Lijnen HR; Van Hoef B; Smith RA; Collen D
Thromb Haemost; 1993 Aug; 70(2):326-31. PubMed ID: 8236143
[TBL] [Abstract][Full Text] [Related]
19. Fibrin-selective thrombolytic therapy with recombinant staphylokinase.
Collen D; Vanderschueren S; Van de Werf F
Haemostasis; 1996 Oct; 26 Suppl 4():294-300. PubMed ID: 8979135
[No Abstract] [Full Text] [Related]
20. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
Kaiser B; Fareed J
Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
